The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.

Min ZhangShuqiang WangBob WilffertRongsheng TongDick van SoolingenSusan van den HofJan Willem C Alffenaar

Published in: British journal of clinical pharmacology (2018)

NAT2 slow acetylation was observed to increase the risk of AT-DILI in tuberculosis patients. Our results support the hypothesis that the slow NAT2 genotype is a risk factor for AT-DILI.

Keyphrases

drug induced
end stage renal disease
mycobacterium tuberculosis
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
hepatitis c virus
pulmonary tuberculosis